Months 4 through 6 and beyond By month four, you are likely at a therapeutic dose that is producing consistent weekly weight loss
Adherence also matters criticallymissing injections or returning to calorie-dense eating interrupts tirzepatide's appetite-suppressing effects
Ikemoto, T., Feng, R., Shimada, M., Saito, Y., Iwahashi, S., Morine, Y., et al
Nutritional deficiencies: Patients who could not eat normally for extended periods report significant malnutrition-related complications
Eating smaller, more frequent meals instead of large meals can also reduce symptoms
The tractability of these dietary, pro-ferroptotic fatty acids addresses the current lack of effective GPX4 inhibitors for use in vivo and suggests an opportunity to exploit a metabolic liability across cancer subtypes